Table 2.

Characteristics of AKI events

AKI (any stage) (%)	51 (16.5)
AKI stage 1	27 (53)
AKI stage 2	11 (22)
AKI stage 3	13 (25)
Receipt of renal replacement therapy	1 (1.9)
Sustained AKI (ie, elevation ≥1.5 times baseline sCr for ≥72 hours) (%)	44 (86)
Non-sustained AKI (ie, elevation ≥1.5 times baseline sCr for <72 hours) (%)	7 (14)
Biopsy- or nephrologist-confirmed nephrotoxicity (%)	12 (24)
Patients with AKI who received ICPi re-challenge (%)	12 (24)
Patients who developed AKI after re-challenge (%)	1 (8.3)
Presumptive AKI etiologies among patients with sustained AKI (%)
Biopsy- or nephrologist-confirmed sustained AKI	12 (27)
Possible ICPi-related AKI	18 (41)
AKI likely related to other causes (eg, pre-renal/hemodynamic, sepsis-related or obstructive AKI)	14 (32)

AKI, acute kidney injury; ICPi, immune checkpoint inhibitors; sCr, serum creatinine.